logo

For the Inventor, By the Inventor

Milpitas, CA, United States of America

Chia-wei Wang

This inventor holds 25 USPTO granted patents and 20 published patent applications and 4 EPO patents, primarily in Biotechnology Proteins. Top assignees: Amunix Operating Inc., Amunix Pharmaceuticals, Inc, Bioverativ Therapeutics Inc.. Active years: 2010-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Chia-wei Wang. Retrieved from https://idiyas.com/inventor/chia-wei-wang-x0iluyb1

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 

% Patents Active = 100.0

 

Average Co-Inventor Count = 6.8

ph-index = 13

Forward Citations = 429(Granted Patents)


Location History:

  • Milpitas, CA (US) (2013 - 2019)
  • Santa Clara, CA (US) (2010 - 2021)

Company Filing History:

goldMedal21 out of 24 
 
Amunix Operating Inc.
 patents
silverMedal3 out of 11 
 
Amunix Pharmaceuticals, Inc
 patents
bronzeMedal1 out of 76 
 
Bioverativ Therapeutics Inc.
 patents

Years Active: 2010-2021

Loading Chart...
Loading Chart...
Areas of Expertise:
Recombinant Polypeptides
Binding Fusion Proteins
Drug Conjugates
Glucose-Regulating Polypeptides
Factor VIII
Coagulation Factors
Growth Hormone
Alpha 1-Antitrypsin
Biologically Active Proteins
Unstructured Recombinant Polymers
XTEN Conjugates
Protein Stability
25 patents (USPTO):Explore Patents
1. 10961287 - Extended recombinant polypeptides and compositions comprising same (2021-03-30),
2. 10953073 - XTEN conjugate compositions and methods of making same (2021-03-23),
3. 10870874 - Binding fusion proteins, binding fusion protein-drug conjugates, XTEN-drug conjugates and methods of making and using same (2020-12-22),
4. 10421798 - Factor VIII compositions and methods of making and using same (2019-09-24),
5. 10172953 - XTEN conjugate compositions and methods of making same (2019-01-08),
6. 10000543 - Glucose-regulating polypeptides and methods of making and using same (2018-06-19),
7. 9976166 - Binding fusion proteins, binding fusion protein-drug conjugates, XTEN-drug conjugates and methods of making and using same (2018-05-22),
8. 9938331 - Biologically active proteins having increased in vivo and/or in vitro stability (2018-04-10),
9. 9926351 - Extended recombinant polypeptides and compositions comprising same (2018-03-27),
10. 9849188 - Growth hormone polypeptides and methods of making and using same (2017-12-26),
11. 9758776 - Coagulation factor IX compositions and methods of making and using same (2017-09-12),
12. 9540430 - Glucose-regulating polypeptides and methods of making and using same (2017-01-10),
13. 9376672 - Coagulation factor IX compositions and methods of making and using same (2016-06-28),
14. 9371369 - Extended recombinant polypeptides and compositions comprising same (2016-06-21),
15. 9249211 - Binding fusion proteins, binding fusion protein-drug conjugates, XTEN-drug conjugates and methods of making and using same (2016-02-02),

Title: Innovations and Contributions of Chia-wei Wang in Biopharmaceuticals

Introduction

Chia-wei Wang, based in Milpitas, California, is a prominent inventor known for his remarkable contributions to the field of biopharmaceuticals. With a portfolio of 25 patents, his work has significantly impacted the development of innovative therapeutic solutions for various health conditions.

Latest Patents

Among his latest patents, two notable inventions stand out. The first is focused on **extended recombinant polypeptides and compositions comprising them**, which involves biologically active proteins linked to an extended recombinant polypeptide (XTEN). This innovation includes isolated nucleic acids that encode these compositions and methods for utilizing them in treating glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders.

The second patent centers around **XTEN conjugate compositions and methods of making them**. This invention relates to XTEN compositions, as well as conjugate compositions that link XTEN to cross-linkers for pharmacologically active payloads. The patent also details methods for producing highly purified XTEN and creating XTEN-linker and XTEN-payload conjugates, enhancing therapeutic efficacy and utility.

Career Highlights

Chia-wei Wang has contributed his expertise to reputable companies, including Amunix Operating Inc. and Amunix Pharmaceuticals, Inc. His innovative work has been pivotal in advancing therapeutic strategies within biopharmaceutical enterprises. Through his patents, Wang has demonstrated a keen ability to blend scientific research with practical applications, showcasing a successful career dedicated to improving human health.

Collaborations

Throughout his career, Chia-wei Wang has collaborated with esteemed professionals in the field, including Volker Schellenberger and Willem P. Stemmer. These partnerships have fostered a rich exchange of ideas and expertise, further enhancing the innovative environment in which he operates.

Conclusion

Chia-wei Wang stands out as a leading inventor in the realm of biopharmaceuticals, with a strong patent portfolio and a history of impactful collaborations. His ongoing work in developing advanced therapeutic compositions continues to contribute to crucial advancements in the treatment of various diseases, solidifying his role as a key figure in innovation and scientific research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…